Results for tag: "Emicizumab"

Emicizumab is a monoclonal antibody used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. It is the first drug of its kind to be approved by the US Food and Drug Administration (FDA) for this condition. The drug works by binding to a protein called factor IX, which helps the body form clots. This helps to reduce the risk of bleeding episodes in people with hemophilia A. Emicizumab is a relatively new drug, but it has already become a major player in the hematological drugs market. It is the first drug to be approved for the treatment of hemophilia A, and it has been shown to be effective in reducing the risk of bleeding episodes. It is also well-tolerated, with few side effects. The companies involved in the emicizumab market include Roche, Chugai Pharmaceuticals, and Genentech. Roche is the manufacturer of the drug, while Chugai and Genentech are responsible for its distribution. Show Less Read more